Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients
Abstract Background OCT-1 gene is a member of the POU-homeodomain family of transcriptional regulators of B-lymphocyte differentiation by controlling expression of B-cell specific genes. BCL-2 gene is a potent inhibitor of apoptosis and it is essential during B-cell differentiation into germinal cen...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-10-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-020-07553-2 |
| _version_ | 1818458223290613760 |
|---|---|
| author | Gisele R. Gouveia Suzete C. Ferreira Sheila A. C. Siqueira Luis Alberto de Pádua Covas Lage Abrahão E. Hallack Neto Renata de Oliveira Costa Juliana Pereira |
| author_facet | Gisele R. Gouveia Suzete C. Ferreira Sheila A. C. Siqueira Luis Alberto de Pádua Covas Lage Abrahão E. Hallack Neto Renata de Oliveira Costa Juliana Pereira |
| author_sort | Gisele R. Gouveia |
| collection | DOAJ |
| description | Abstract Background OCT-1 gene is a member of the POU-homeodomain family of transcriptional regulators of B-lymphocyte differentiation by controlling expression of B-cell specific genes. BCL-2 gene is a potent inhibitor of apoptosis and it is essential during B-cell differentiation into germinal center. These genes may be expressed in diffuse large B-cell lymphoma (DLBCL), but the role of BCL-2 in its prognosis has been contradictory, and OCT-1 has yet to be tested. Methods In this study, we aimed to investigate the prognostic impact of OCT-1 and BCL-2 expression in DLBCL treated in the real world with immunochemotherapy in a single center. BCL-2 and OCT-1 genes were available in 78.5% (77/98) DLBCL patients, and the RNA for quantitative real-time PCR was isolated from formalin-fixed paraffin-embedded samples. The values obtained for gene expression were transformed in categorical variable according to their median. Results Cohort median age was 54.5 years (15–84), 49 (50%) were male, 38/77 (49.4%) and 40/77 (51.9%) presented OCT-1 and BCL-2 expression ≥ median, respectively. The overall response rate (ORR) in all patients was 68.4% (67/98), 65,3% (64/98) of patients acquired complete response, and 3.1% (3/98) partial response, while 6.1% (6/98) were primary refractory. The median follow-up was 3.77 years (95% CI: 3.2–4.1), with 5.43 (95% CI: 2.2-NR) of overall survival (OS) and 5.15 years (95% CI: 2.9-NA) of progression free survival (PFS). OCT-1 ≥ median was associated with shorter OS at univariate analysis (p = 0.013; [HR] 2.450, 95% CI: 1.21–4.96) and PFS (p = 0.019; [HR] 2.270, 95%CI: 1.14–4.51) and BCL-2 gene overexpression presented worse PFS (p = 0.043, [HR] 2.008, 95% CI: 1.02–3.95). At multivariate analysis, OCT-1 overexpression was associated with poor PFS (p = 0.035, [HR] 2.22, 95% CI: 1.06–4.67). Conclusion In this study, we showed that overexpression of OCT1 gene was an independent prognostic factor of adverse outcomes in DLBCL. |
| first_indexed | 2024-12-14T22:55:02Z |
| format | Article |
| id | doaj.art-4df2e8579d1d425188c83eb3659ef18c |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-14T22:55:02Z |
| publishDate | 2020-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-4df2e8579d1d425188c83eb3659ef18c2022-12-21T22:44:37ZengBMCBMC Cancer1471-24072020-10-012011910.1186/s12885-020-07553-2Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patientsGisele R. Gouveia0Suzete C. Ferreira1Sheila A. C. Siqueira2Luis Alberto de Pádua Covas Lage3Abrahão E. Hallack Neto4Renata de Oliveira Costa5Juliana Pereira6Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo’s Medical School (FM-USP)Department of Molecular Biology, Pró-Sangue Foundation, Sao Paulo Blood BankDepartment of Pathology, Hospital das Clínicas – Faculty of Medicine, Sao Paulo University (HC-FM-USP)Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo’s Medical School (FM-USP)Department of Hematology and Hemotherapy, University of Juiz de Fora (UJF)Department of Hematology and Hemotherapy, Centro Universitário Lusíadas (FCMS/UNILUS)Department of Hematology, Hemotherapy and Cell Therapy, Faculty of Medicine, Sao Paulo University (FM-USP)Abstract Background OCT-1 gene is a member of the POU-homeodomain family of transcriptional regulators of B-lymphocyte differentiation by controlling expression of B-cell specific genes. BCL-2 gene is a potent inhibitor of apoptosis and it is essential during B-cell differentiation into germinal center. These genes may be expressed in diffuse large B-cell lymphoma (DLBCL), but the role of BCL-2 in its prognosis has been contradictory, and OCT-1 has yet to be tested. Methods In this study, we aimed to investigate the prognostic impact of OCT-1 and BCL-2 expression in DLBCL treated in the real world with immunochemotherapy in a single center. BCL-2 and OCT-1 genes were available in 78.5% (77/98) DLBCL patients, and the RNA for quantitative real-time PCR was isolated from formalin-fixed paraffin-embedded samples. The values obtained for gene expression were transformed in categorical variable according to their median. Results Cohort median age was 54.5 years (15–84), 49 (50%) were male, 38/77 (49.4%) and 40/77 (51.9%) presented OCT-1 and BCL-2 expression ≥ median, respectively. The overall response rate (ORR) in all patients was 68.4% (67/98), 65,3% (64/98) of patients acquired complete response, and 3.1% (3/98) partial response, while 6.1% (6/98) were primary refractory. The median follow-up was 3.77 years (95% CI: 3.2–4.1), with 5.43 (95% CI: 2.2-NR) of overall survival (OS) and 5.15 years (95% CI: 2.9-NA) of progression free survival (PFS). OCT-1 ≥ median was associated with shorter OS at univariate analysis (p = 0.013; [HR] 2.450, 95% CI: 1.21–4.96) and PFS (p = 0.019; [HR] 2.270, 95%CI: 1.14–4.51) and BCL-2 gene overexpression presented worse PFS (p = 0.043, [HR] 2.008, 95% CI: 1.02–3.95). At multivariate analysis, OCT-1 overexpression was associated with poor PFS (p = 0.035, [HR] 2.22, 95% CI: 1.06–4.67). Conclusion In this study, we showed that overexpression of OCT1 gene was an independent prognostic factor of adverse outcomes in DLBCL.http://link.springer.com/article/10.1186/s12885-020-07553-2Diffuse large B-cell lymphoma (DLBCL)OCT-1 geneBCL-2 genePrognosisImmunochemotherapy |
| spellingShingle | Gisele R. Gouveia Suzete C. Ferreira Sheila A. C. Siqueira Luis Alberto de Pádua Covas Lage Abrahão E. Hallack Neto Renata de Oliveira Costa Juliana Pereira Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients BMC Cancer Diffuse large B-cell lymphoma (DLBCL) OCT-1 gene BCL-2 gene Prognosis Immunochemotherapy |
| title | Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients |
| title_full | Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients |
| title_fullStr | Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients |
| title_full_unstemmed | Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients |
| title_short | Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients |
| title_sort | overexpression of oct 1 gene is a biomarker of adverse prognosis for diffuse large b cell lymphoma dlbcl data from a retrospective cohort of 77 brazilian patients |
| topic | Diffuse large B-cell lymphoma (DLBCL) OCT-1 gene BCL-2 gene Prognosis Immunochemotherapy |
| url | http://link.springer.com/article/10.1186/s12885-020-07553-2 |
| work_keys_str_mv | AT giselergouveia overexpressionofoct1geneisabiomarkerofadverseprognosisfordiffuselargebcelllymphomadlbcldatafromaretrospectivecohortof77brazilianpatients AT suzetecferreira overexpressionofoct1geneisabiomarkerofadverseprognosisfordiffuselargebcelllymphomadlbcldatafromaretrospectivecohortof77brazilianpatients AT sheilaacsiqueira overexpressionofoct1geneisabiomarkerofadverseprognosisfordiffuselargebcelllymphomadlbcldatafromaretrospectivecohortof77brazilianpatients AT luisalbertodepaduacovaslage overexpressionofoct1geneisabiomarkerofadverseprognosisfordiffuselargebcelllymphomadlbcldatafromaretrospectivecohortof77brazilianpatients AT abrahaoehallackneto overexpressionofoct1geneisabiomarkerofadverseprognosisfordiffuselargebcelllymphomadlbcldatafromaretrospectivecohortof77brazilianpatients AT renatadeoliveiracosta overexpressionofoct1geneisabiomarkerofadverseprognosisfordiffuselargebcelllymphomadlbcldatafromaretrospectivecohortof77brazilianpatients AT julianapereira overexpressionofoct1geneisabiomarkerofadverseprognosisfordiffuselargebcelllymphomadlbcldatafromaretrospectivecohortof77brazilianpatients |